Skip to main content

Table 1 Baseline characteristics of 417 patients classified as having a poor prognosis or a non-poor prognosis

From: Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis

  Poor prognosis patients Non-poor prognosis patients  
  Initial mono Initial combo Initial mono Initial combo P-value
(n =100) (n =92) (n =100) (n =125)  
Age, years, mean ± SD 56 ± 13 58 ± 15 53 ± 13 51 ± 13 0.002
Gender, n (%) female 68 (68) 60 (65) 72 (72) 78 (62) 0.481
Treatment strategy, n (%)      <0.001
1. Sequential monotherapy (MTX) 51 (51) 0 54 (54) 0  
2. Step-up therapy (MTX) 49 (49) 0 46 (46) 0  
3. MTX, SSA and prednisone 0 43 (47) 0 61 (49)  
4. MTX and infliximab 0 49 (53) 0 64 (51)  
Disease activity score, mean ± SD 4.8 ± 0.7 4.5 ± 0.6 4.3 ± 0.9 4.1 ± 0.9 <0.001
Swollen joint count, median (IQR) 17 (11-22) 15 (12-18) 11 (8-16) 11 (8-17) <0.001
Tender joint count, median (IQR) 14 (11-19) 13 (10-19) 13 (8-16) 12 (8-17) <0.001
ESR, mean ± SD 51 ± 30 44 ± 29 37 ± 25 35 ± 24 <0.001
VAS gh, mean ± SD 61 ± 21 57 ± 22 60 ± 23 60 ± 21 0.754
HAQ, mean ± SD 1.4 ± 0.7 1.4 ± 0.7 1.3 ± 0.7 1.3 ± 0.7 0.633
RF-positive, n (%) 85 (85) 79 (86) 49 (49) 54 (43) <0.001
ACPA-positive, n (%) 87 (89) 76 (84) 40 (41) 49 (40) <0.001
Erosive disease, n (%) 79 (81) 78 (85) 62 (63) 74 (60) <0.001
  1. ACPA, anti-citrullinated autoantibodies; Erosive disease, defined as the presence of >0.5 erosion on radiographs of hands and feet; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire (0 to 3 scale); Initial combo, initial combination therapy with either prednisone or infliximab; Initial mono, initial monotherapy with methotrexate; MTX, methotrexate; Non-poor prognosis patients (presence of ≤2 of 4 poor prognostic factors); Poor prognosis patients (presence of ≤3 of 4 poor prognostic factors); RF, IgM rheumatoid factor; SSA, sulphasalazine; VAS gh, visual analogue scale (0 to 100 millimeter scale) of general health.